Clinical trials: MAB
RSV Infection
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
Gates MRI-RSM01-101 was a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, occurrence of Anti-drug antibody (ADA), and assessment of…
- Trial name
- NCT05118386
- Testing
- RSM01
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Ovarian Neoplasms
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart.
- Trial name
- NCT00034372
- Testing
- oregovomab
- Where
- 17 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Unither Pharmaceuticals
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated
Hidradenitis Suppurativa (HS)
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS).
- Trial name
- NCT07554014
- Testing
- IL-17A/F mAb + NAFL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ventilator Associated Pneumonia, Staphylococcus Aureus
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE-2 (NCT05331885)
- Testing
- Suvratoxumab
- Where
- 27 sites in Belgium, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Advanced Solid Tumors or Lymphoma
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma…
- Trial name
- NCT03821363
- Testing
- SCT-I10A
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sinocelltech Ltd.
Colorectal Neoplasms
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
- Trial name
- NCT03659448
- Testing
- SGM-101
- Where
- 11 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Surgimab
COVID-19
Study of VYD2311 for the Prevention of COVID-19
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19.
- Trial name
- DECLARATION (NCT07298434)
- Testing
- VYD2311-SD, VYD2311-MD
- Where
- 20 sites in United States
- Volunteers
- 1,770 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Liver Carcinoma
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.
- Trial name
- NCT00791544
- Testing
- AVE1642, sorafenib, erlotinib
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Sanofi
Recurrent Glioblastoma
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.
- Trial name
- NCT03856099
- Testing
- TTAC-0001
- Where
- 3 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- PharmAbcine
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
- Trial name
- NCT00435916
- Testing
- SGN-40
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Seagen Inc.
Myelodysplastic Syndromes
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003984
- Testing
- lintuzumab
- Where
- 27 sites in Austria, Belgium and 7 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Aplastic Anemia
Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia
Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic…
- Trial name
- NCT01759732
- Testing
- Fludarabine, Cyclophosphamide, anti-thymocyte globulin
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Asan Medical Center
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
- Trial name
- NCT00060671
- Testing
- rituximab, Pixantrone (BBR 2778)
- Where
- 38 sites in United States
- Volunteers
- 800 people
- Sponsor
- CTI BioPharma
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
The goal of this clinical research study is to find the best combination of oxaliplatin, bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with advanced cancer that has spread to the liver.
- Trial name
- NCT00941499
- Testing
- HAI Oxaliplatin, 5-FU, Bevacizumab
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
HIV-1-infection
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- NCT05275998
- Testing
- TMB-365/TMB-380
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- TaiMed Biologics Inc.
Healthy Volunteer
A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers
This randomized, observer-blinded, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5469754 in healthy volunteers.
- Trial name
- NCT01620931
- Testing
- RO5469754
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.